About Us

Headquartered in Kentucky, a hub for agbiotech, Demeetra Agbio was launched in 2019 as a spin out of Transposagen Biopharmaceuticals, Inc. We have experienced management and Board of Directors with over 50+ years of combined experience in the advancing our lead therapeutic compound biotechnology and drug development space.

Mask Group 19

Jack Crawford M.S.

CEO

Mr. Crawford has held multiple leadership positions in start-up and emerging gene editing and drug discovery companies Transposagen Biopharmaceuticals, and Hera BioLabs. He has experience in private equity financing, product development, licensing, technology and patent evaluation. Mr. Crawford holds a BS in Biochemistry from Virginia Tech and a Masters in Biotechnology from University of Pennsylvania.

Mask Group 18

Eric Ostertag - M.D., Ph.D.

Chairman of the Board

Dr. Ostertag is the founder multiple biotechnology companies which he has helped built into successes, including Transposagen, Hera BioLabs and Poseida Therapeutics. He has served as chief executive officer of Poseida and as a member of the board of directors since May 2015. Dr. Ostertag received both his Ph.D. in molecular biology and his M.D. from the University of Pennsylvania School of Medicine and his B.S. in genetics from the University of Wisconsin-Madison. Dr. Ostertag is the Founder of Demeetra and brings his expertise to our strategy and execution as the Chairman of our Board of Directors.

Mask Group 17

Kevin Slawin, M.D.

Board of Directors Member

Dr. Slawin is the founder of multiple biotech companies, including Bellicum Pharmaceuticals. He has 20+ years of CMO/CTO experience and has significant private equity financing experience.

kyle

Kyle Rector

Senior Scientist

Kyle was trained at the University of Kentucky (UKY) in the fields of Agricultural Biotechnology and Human Physiology. He was among the first employees at Demeetra. His core competencies are in molecular genetics and gene editing, which span mammalian, yeast, and plant systems. Prior to joining Demeetra, Kyle was with Evolva, a global synthetic biotechnology company. As R&D Director at Demeetra, Kyle is responsible for the implementation gene editing technology applications in plant trait development and metabolic engineering.